BioMarin acquires ZyStor

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) acquired ZyStor Therapeutics Inc. (Milwaukee, Wis.) for $22 million up front plus up to $93 million in potential milestone payments. BioMarin gains ZyStor's ZC-701, which is slated to enter Phase I/II testing to treat Pompe's disease in 1Q11. ZC-701 is a fusion of insulin-like growth factor-2 (IGF-2) and acid alpha glucosidase (GAA) that uses ZyStor's Glycosylation Independent Lysosomal Targeting (GILT) technology. ...